# US 2009/0221701 A1 · Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221701 A1
- Document ID: US20090221701A1
- Status: Published application
- Kind: A1
- Application number: 12/453,470
- Filed: 2009-05-12
- Published: 2009-09-03
- Earliest claimed: 2000-08-01
- Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- Inventors: Arduino Arduini
- Web page: https://patentgrep.com/patent/US20090221701A1

## CPC

- A61K 31/195: having an amino group
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The use of fibrates, particularly clofibrate, is described for the preparation of a medicament useful in the treatment of congestive heart failure.

## Claims

### Claim at position 1

-4. (canceled)

### Claim 5

A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a congestive heart failure subject comprising administering to a subject in need of the same an effective amount of a ligand of PPARα or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said ligand of PPARα is a fibrate or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said fibrate is selected form the group consisting of gemfibrozil, phenofibrate, ciprofibrate and clofibrate or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said fibrate is clofibrate or a pharmaceutically acceptable salt thereof.

### Claim 9

A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a congestive heart failure subject comprising administering to a subject in need of the same an effective amount of a ligand of PPARα, said ligand of PPARα being devoid of CPT1 inhibitory activity or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said ligand of PPARα is a fibrate or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said fibrate is selected form the group consisting of gemfibrozil, phenofibrate, ciprofibrate and clofibrate or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said fibrate is clofibrate or a pharmaceutically acceptable salt thereof.

### Claim 13

A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a subject being affected by heart failure unrelated to dyslipidaemic states, comprising administering to a subject in need of the same an effective amount of a ligand of PPARα, said ligand of PPARα being devoid of CPT1 inhibitory activity or a pharmaceutically acceptable salt thereof.

### Claim 14

The method according to 13, wherein said ligand of PPARα is a fibrate or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said fibrate is selected form the group consisting of gemfibrozil, phenofibrate, ciprofibrate and clofibrate or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said fibrate is clofibrate or a pharmaceutically acceptable salt thereof.

### Claim 17

A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a congestive heart failure subject comprising administering to a subject in need of the same an effective amount of clofibrate or a pharmaceutically acceptable salt thereof.

### Claim 18

A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a subject being affected by heart failure unrelated to dyslipidaemic states, comprising administering to a subject in need of the same an effective amount of clofibrate or a pharmaceutically acceptable salt thereof.
